Gilead Sciences, an American biopharmaceutical company, completed the acquisition of Immunomedics, a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer, for $21bn. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer. Together we will bring Trodelvy to many more patients around the world with triple-negative breast cancer and continue to explore its potential in many other types of cancer, both as a monotherapy and in combination with other treatments,” Daniel O’Day, Gilead Sciences Chairman and CEO.